Karolinska Management Changes
This article was originally published in Scrip
Executive Summary
Karolinska Development AB has appointed life science investor Viktor Drvota chief investment officer, while the company's deputy CEO and chief scientific officer, Terje Kalland, will retire from both positions – effective Dec. 31, 2015. Drvota was previously head of life science and a senior investment manager at SEB Venture Capital. Prior to this he was a practising cardiologist at Huddinge University Hospital in Stockholm for 11 years and associate professor in cardiology at Karolinska Institute, Stockholm, since 2002.